Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06397560 · ClinicalTrials.gov registry record · NA

PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial

A NA study of Glioma and Glioma, Malignant, sponsored by Baptist Health South Florida.

Recruiting
Registry status
NA
Development phase
28
Enrollment target
2
Study locations

NCT06397560: Recruiting NA study of Glioma and Glioma, Malignant, sponsored by Baptist Health South Florida.

NCT06397560 is a NA study of Glioma and Glioma, Malignant that is actively recruiting participants, run by Baptist Health South Florida. The registered enrollment target is 28 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06397560, a NA study of Glioma and Glioma, Malignant, is actively recruiting participants, sponsored by Baptist Health South Florida.

RECRUITING
Registry status
NA
Development phase
28 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this research study is to see if a specific type of radiation therapy, called "proton pulsed reduced dose rate" or "PRDR radiotherapy" has any benefits at dose levels and number of fractions thought to be acceptable in earlier research studies. The researchers want to find out what effects (good and bad) PRDR has on people with cancer in the brain called a "recurrent high-grade glioma" meaning that it grows fast, can spread quickly, and it has come back or gotten worse after being treated previously.

Primary Outcome

PFS is defined as the duration of time from treatment start to first progressive disease (PD), date of death, or last follow-up date on which the patient was reported alive after proton PRDR reirradiation. Response to treatment will be assessed using Response Assessment in Neuro-Oncology (RANO).

Interventions

  • RADIATION PRDR

Study Locations (2)

Florida

  • Lynn Cancer Institute at Baptist Health, Inc. - Boca Raton
  • Miami Cancer Institute at Baptist Health, Inc. - Miami

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2025-04-30
Est. Completion 2029-06
Phase NA
Baptist Health South Florida

40 total trials

What NCT06397560 shows while recruiting

NCT06397560 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (87% lower).

The record links to 3 conditions, with Glioma appearing as the primary indexed condition, and to 1 intervention - of which PRDR is the first listed.

NCT06397560 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT06397560 about?

NCT06397560 is a clinical study titled "PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial". The purpose of this research study is to see if a specific type of radiation therapy, called "proton pulsed reduced dose rate" or "PRDR radiotherapy" has any benefits at dose levels and number of fractions thought to be acceptable in earlier research studies. The researchers want to find out what ef...

What is the current status of trial NCT06397560?

This trial is currently recruiting. It is a NA study. The enrollment target is 28 participants. The study started on 2025-04-30. Estimated completion is 2029-06.

What conditions does trial NCT06397560 study?

This clinical trial studies the following conditions: Glioma, Glioma, Malignant, Recurrent Glioma.

What interventions are being tested in trial NCT06397560?

The interventions under investigation include: PRDR (RADIATION).

Who is sponsoring clinical trial NCT06397560?

This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06397560 being conducted?

This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glioma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06397560's enrollment target sits among peer trials

28 59th of 87 higher than 27 of 87 other Glioma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06397560, the US trial registry maintained by the National Library of Medicine. NCT06397560 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.